Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,840 across all filing types
Latest filing 2026-03-19 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
2025年年度报告
Annual Report Classification · 100% confidence The document is titled "普洛药业股份有限公司2025 年年度报告全文" which translates to "Apeloa Pharmaceutical Co., Ltd. 2025 Annual Report Full Text." It contains detailed sections including company overview, financial data, management discussion and analysis, governance, risk factors, and audited financial statements. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. It includes audited financial figures, management analysis, and detailed business descriptions typical of an official annual report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2025
2026-03-19 Chinese
独立董事述职报告(钱娟萍)
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2025, detailing the independent director's attendance, duties, committee work, communication with auditors, and overall fulfillment of responsibilities during the year. It is a narrative report on the director's activities and oversight rather than a financial report, audit report, or regulatory filing. It does not contain financial statements or audit opinions but focuses on governance and director duties. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management activities and reports on their roles and responsibilities.
2026-03-19 Chinese
独立董事述职报告(陈凌)
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report" for the year 2025, detailing the independent director's attendance, participation, and duties performed during the year. It includes descriptions of meetings attended, committees served on, voting behavior, and efforts to protect shareholder interests. The document is a narrative report on the director's activities and responsibilities rather than a financial report, audit, or regulatory filing. It does not contain financial statements or earnings data, nor is it an announcement or proxy solicitation. This type of document fits best under Board/Management Information (MANG), as it relates to the activities and reports of a board member.
2026-03-19 Chinese
独立董事提名人与候选人声明与承诺（徐升艳）
Board/Management Information Classification · 95% confidence The document is a detailed nomination and declaration statement for an independent director candidate for a company's board. It includes statements of qualifications, compliance with regulatory requirements, and commitments related to the candidate's independence and eligibility. There are no financial statements, earnings data, or management discussion of financial results. The content is focused on board/management information, specifically the nomination and declaration of a board member candidate. This fits the category of Board/Management Information (MANG). The document length is sufficient and contains substantive content, not just an announcement or a brief notice, so it is not a Regulatory Filing or Report Publication Announcement. Therefore, the appropriate classification is MANG with high confidence.
2026-03-19 Chinese
关于2026年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's expected related party transactions for the fiscal year 2026. It includes transaction categories, counterparties, pricing principles, estimated and actual amounts, and board and independent director approvals. It is not a full financial report but a regulatory disclosure about related party transactions, which is typical for regulatory filings. The document length is 7570 characters, which is substantial but the content is focused on related party transaction disclosures rather than comprehensive financial statements or management discussion. There is no indication that this is an annual report, interim report, earnings release, or other financial report. It is also not a proxy statement, voting result, or management change announcement. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2026-03-19 Chinese
普洛药业股份有限公司董事会审计委员会对会计师事务所2025年度履行监督职责情况的评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report by the Board Audit Committee on the performance of the accounting firm in supervising audit duties for the fiscal year 2025. It discusses the assessment and reappointment of the audit firm, communication mechanisms, supervision of audit quality, and an evaluation of the audit firm's professional capabilities and audit quality. It references the 2025 annual report and related audit work but does not contain the actual financial statements or detailed financial data itself. The document is a standalone audit-related report focusing on the audit firm's performance and oversight rather than the full annual report or financial statements. Given its content and length (1408 characters), it fits best as an Audit Report / Information (AR) rather than a full Annual Report (10-K) or a report publication announcement (RPA). FY 2025
2026-03-19 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.